Korean J Hematol 2009; 44(4):
Published online December 30, 2009
https://doi.org/10.5045/kjh.2009.44.4.304
© The Korean Society of Hematology
이성은, 이석, 조병식, 임기성, 김유진, 김희지, 민창기, 조석구,
김동욱, 이종욱, 민우성, 박종원, 김춘추
가톨릭대학교 의과대학 서울성모병원 소혈모세포이식센터 혈액내과
Acute graft-versus-host disease (GVHD) is one of the most severe complications following allogeneic stem cell transplantation (SCT), and involvement of the gut has been associated with increased mortality and a poorer response to high-dose systemic corticosteroids. For over a decade, oral beclomethasone dipropionate (BDP) has been studied in the treatment of acute gastrointestinal GVHD, as a monotherapy, or in combination with systemic corticosteroids. Here we report, for the first time in Korea, the efficacy of oral BDP (8 mg/day for 25 days) in 3 adults with acute lymphoblastic leukemia who developed steroid-refractory gastrointestinal GVHD (grade III) after myeloablative conditioning SCT (1 matched sibling transplant, 2 matched unrelated transplants). All patients responded completely to oral BDP treatment. Oral BDP is safe and effective for the control of steroid-refractory acute gastrointestinal GVHD. (Korean J Hematol 2009;44:304-309.)
Keywords Oral beclomethasone dipropionate, Allogeneic stem cell transplantation, Gastrointestinal acute graft-versus-host disease
Korean J Hematol 2009; 44(4): 304-309
Published online December 30, 2009 https://doi.org/10.5045/kjh.2009.44.4.304
Copyright © The Korean Society of Hematology.
이성은, 이석, 조병식, 임기성, 김유진, 김희지, 민창기, 조석구,
김동욱, 이종욱, 민우성, 박종원, 김춘추
가톨릭대학교 의과대학 서울성모병원 소혈모세포이식센터 혈액내과
Sung Eun Lee, Seok Lee, Byung Sik Cho, Ki Seong Eom, Yoo Jin Kim, Hee Je Kim, Chang Ki Min, Seok Goo Cho, Dong Wook Kim, Jong Wook Lee, Woo Sung Min, Chong Won Park, Chun Choo Kim
Department of Hematology, Catholic Blood and Marrow Transplantation Center, College of Medicine, The Catholic University of Korea, Seoul, Korea
Acute graft-versus-host disease (GVHD) is one of the most severe complications following allogeneic stem cell transplantation (SCT), and involvement of the gut has been associated with increased mortality and a poorer response to high-dose systemic corticosteroids. For over a decade, oral beclomethasone dipropionate (BDP) has been studied in the treatment of acute gastrointestinal GVHD, as a monotherapy, or in combination with systemic corticosteroids. Here we report, for the first time in Korea, the efficacy of oral BDP (8 mg/day for 25 days) in 3 adults with acute lymphoblastic leukemia who developed steroid-refractory gastrointestinal GVHD (grade III) after myeloablative conditioning SCT (1 matched sibling transplant, 2 matched unrelated transplants). All patients responded completely to oral BDP treatment. Oral BDP is safe and effective for the control of steroid-refractory acute gastrointestinal GVHD. (Korean J Hematol 2009;44:304-309.)
Keywords: Oral beclomethasone dipropionate, Allogeneic stem cell transplantation, Gastrointestinal acute graft-versus-host disease
Seung-Ah Yahng, Jae-Ho Yoon, Seung-Hwan Shin, Sung-Eun Lee, Ki-Seong Eom, and Yoo-Jin Kim
Blood Res 2013; 48(2): 145-148Gak Won Yun, Ik Chan Song, Seon Ah Jin, Young Joon Yang, Nam Hwan Park, Hyo Jin Lee, Hwan Jung Yun, Sam yong Kim, Deog Yeon Jo
Korean J Hematol 2008; 43(3): 194-197Yoon Hee Park, Seok Lee, Yoo Jin Kim, Dong Gun Lee, Chi Young Park, Ho Jin Shin, Hee Je Kim, Chang Ki Min, Dong Wook Kim, Jong Wook Lee, Woo Sung Min, Chun Choo Kim
Korean J Hematol 2002; 37(2): 127-133